FOXO3 and chronic kidney disease: Our findings confirm that upregulation of p66Shc and FoxO3a expression in the skeletal muscle of CKD-LPD rats and, importantly, treatment with KA decreases the expression of both p66Shc and FoxO3a in CKD + LPD rats.